ArticleLeukemia & lymphoma2017
Marginal zone dural lymphoma: the Memorial Sloan Kettering Cancer Center and University of Miami experiences.
Article in Leukemia & lymphoma, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Survival Outcomes and Prognostic Factors in Patients With Primary Central Nervous System Low-Grade B-Cell Lymphoma: A Population-Based Cohort Study.Cancer medicine · 2026Article
- Dural Lymphomas Unmasked: A Narrative Review of Extra-Axial Mimics and a Pragmatic Diagnostic Decision Algorithm.Cancers · 2026Review
- Primary Spinal Marginal Zone Lymphoma Presenting With Spinal Cord Compression: A Case Report.Cureus · 2026Article
- Article
- Article
- Intracranial MALT lymphomas of the dura mater: two case reports.Acta neurologica Belgica · 2023Article
- A Meningioma Mimic and Distinct Subtype of Primary Central Nervous System Lymphoma: Primary Dural Lymphoma.Journal of hematology · 2023Article
- Primary pituitary stalk mucosa-associated lymphoid tissue lymphoma: a case report and literature review.Frontiers in neurology · 2023Article
- Chemotherapy is an efficient treatment in primary CNS MALT lymphoma.Journal of neuro-oncology · 2022Article
- Rare central nervous system lymphomas.British journal of haematology · 2022Review
- Marginal zone lymphoma: present status and future perspectives.Haematologica · 2022Article
- Patients with marginal zone dural lymphoma successfully treated with rituximab and bendamustine: A report of two cases.Molecular and clinical oncology · 2021Article
- Primary marginal zone B-cell lymphoma of the cavernous sinus: a case report and review of the literature.BMC medical imaging · 2021Review
- How we treat mature B-cell neoplasms (indolent B-cell lymphomas).Journal of hematology & oncology · 2021Review
- Primary Dural Lymphoma Mimicking En Plaque Cerebellopontine Angle Meningioma.Case reports in pathology · 2021Article
- Whole brain radiation therapy for primary central nervous system marginal zone lymphoma: a case report.International cancer conference journal · 2021Article
- Marginal zone lymphoma of the dura - two case reports with long-term follow-up.Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology · 2021Article
- Primary Central Nervous System Lymphomas: A Diagnostic Overview of Key Histomorphologic, Immunophenotypic, and Genetic Features.Diagnostics (Basel, Switzerland) · 2020Review
- Ibrutinib-based therapy for the treatment of marginal zone lymphoma with central nervous system involvement.Leukemia & lymphoma · 2020Article
- Primary central nervous system marginal zone B-cell lymphoma arising from the dural meninges: A case report and review of literature.Clinical case reports · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Dural lymphoma (DL) is a rare type of primary CNS lymphoma arising from the dura mater. The optimal treatment is uncertain. A retrospective review was performed on 26 DL patients. Seventeen patients underwent resection and nine had a biopsy. Twenty three patients could be assessed for a response to treatment after surgery. Thirteen received focal radiotherapy (RT), six whole brain RT (WBRT), three chemotherapy alone and one chemotherapy followed by WBRT. Twenty two achieved complete response (CR) and one a partial response (PR). Four patients relapsed (two local and two systemic). Median follow up was 64 months, with median progression free survival (PFS) and OS not reached. Three year PFS was 89% (95% CI 0.64-0.97). All patients are alive at last follow-up, demonstrating that DL is an indolent tumor with long survival. CR is achievable with focal therapy in the majority of cases, but there is a risk for relapses and long-term follow-up is recommended.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.